Corporate Member Update: Merck- Keytruda®

Merck would like to inform you that the FDA has approved KEYTRUDA® (pembrolizumab) Injection 100 mg for the treatment of patients with locally advanced cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation. This follows the 2020 approval of KEYTRUDA to treat patients with recurrent or metastatic cSCC that is not curable by surgery or radiation.

To read the full press release, please click here.